Khadija Rebbani and Kyoko Tsukiyama-Kohara
The sustained increase of hepatocellular carcinoma (HCC) new cases and the failure of determining a “universal” biomarker for early detection are sounding the alarm about finding urgently new alternatives and develop new biomarkers in order to face this public health issue. Hereby, a highlight of new findings about the involvement of 3β-hydroxysterol Δ24-reductase (DHCR24) as a potential biomarker of hepatitis C disease progression to hepatocellular carcinoma and a valuable target for hepatitis C virus (HCV) related HCC therapy.